Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 2 of 5 peers filed FY2024. Switch to FY2023 (3 of 5).
| Line item | Elelgrupi | Pip Company | Grasse Pharma Georgia | Sando Pharma | Medimex |
|---|---|---|---|---|---|
| Total Revenue | 1,524 | 1,276 | — | — | — |
| Total COGS | -710 | -1,174 | — | — | — |
| Gross Profit | 814 | 102 | — | — | — |
| Gross Margin | 53.4% | 8.0% | — | — | — |
| Total Operating Expenses | -446 | -301 | — | — | — |
| EBITDA | 368 | -198 | — | — | — |
| EBITDA Margin | 24.1% | -15.5% | — | — | — |
| Total D&A | 0 | -1 | — | — | — |
| EBIT / Operating Income | 368 | -199 | — | — | — |
| Profit Before Tax | 368 | -309 | — | — | — |
| Total Income Tax | -55 | 0 | — | — | — |
| Net Profit / (Loss) | 313 | -309 | — | — | — |
| Net Margin | 20.6% | -24.2% | — | — | — |
| Total Other Income | — | -110 | — | — | — |
Not every picked company reports every selected year — FY2024: 3 of 5 companies have no filing. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Elelgrupi | Pharma | 24.1% | 65th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Grasse Pharma Georgia | Pharma | — | no FY data | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
| Medimex | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.